T2 Biosystems is a biotechnology company focused on transforming the way infectious diseases are diagnosed
The company's innovative molecular diagnostic platform enables rapid and accurate detection of a wide range of pathogens, including bacteria and fungi, using blood samples. By providing timely results, T2 Biosystems aims to enhance clinical decision-making, improve patient outcomes, and reduce the overall burden of infectious diseases. Their commitment to developing advanced diagnostic tools positions them as a leader in the field of point-of-care testing and infectious disease management.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Shares of Riot Platforms, Inc. (NASDAQRIOT) rose sharply in today's pre-market trading amid a rise in Bitcoin. Bitcoin (CRYPTO: BTC) prices gained around 1.5% over the past 24 hours to $66,012 this morning.
Shares of Big Lots, Inc. (NYSEBIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.
T2 Biosystems said that it has received FDA clearance to add the capability to detect another bacterial species, Acinetobacter baumannii, to the panel. "We are thrilled to receive the FDA 510(k) clearance for the expanded T2Bacteria Panel, to include the detection of A. baumannii, as we believe it will lead to increased adoption of our proprietary direct-from-blood platform," stated John Sperzel, CEO of T2 Biosystems.
